INTRODUCTION
Continued improvements in the management of UC are need-bleeding and normal mucosal appearance on endoscopy. 10, 13 Even when remission is achieved, the majority of the patients experience a relapse at some point. 14, 15 Rapid treatment and resolution of relapses is a key treatment requirement as active disease has many negative impacts for patients, healthcare systems and society. Active UC is associated with reduced quality of life (QoL) for patients, [16] [17] [18] [19] higher utilization of healthcare resources, [20] [21] [22] and personal costs to patients, such as time off work and reduced productivity. 23, 24 Therefore, improvements to the treatment of disease flares in mild-to-moderate UC patients is beneficial.
iSTART i Support Therapy-Access to Rapid Treatment (iSTART) is an initiative to improve patient-centered management to UC. The iSTART initiative gives mild-to-moderate UC patients (selected by their physician) the ability to self-assess UC symptomology, increase dosing of first-line therapy to an optimized level and self-start second-line treatment. iSTART is designed to fit within the framework supplied by published treatment guidelines. Clinicians should select only the most appropriate patients, including, for example: those at a high risk of relapse, those with limited access to healthcare services, those who take an active interest in their disease and its treatment, and those at a low risk of Clostridium difficile infection. Under iS-TART, patients on optimized first-line therapy will be provided with training on how to identify a symptomatic flare, and provided with a prescription for second-line treatment for use when optimized first-line treatment is insufficient to maintain remission. If the patient experiences a flare they will self-start a short course of second-line therapy whilst contacting their clinic who will manage any ongoing treatment. The short course prescribed ensures that patients cannot self-medicate unsupervised and iSTART emphasizes that clinicians must be informed if the prescription is used to allow long-term changes in disease management. The iSTART approach will allow for the fast treatment of flares, producing benefits for patients and healthcare systems. For patients, iSTART aims to improve day-to-day QoL and to create a sense of empowerment over their disease. Empowering patients to reliability self-assess a UC flare would allow faster commencement of second-line therapy, reducing the duration of active disease and associated damage and reduced patient QoL. Furthermore, this would reduce the number of patients seeking emergency healthcare, decreasing the clinical and healthcare burden of mild-to-moderate UC treatment. iS-TART will also provide additional support to patients with limited access to their physician, such as those whose location or distance from their physician leave them unable to access timely treatment, and allow them access to rapid care that is currently unavailable to them.
iSTART will need to be adapted into an appropriate form to fit around different healthcare systems and local populations. This consensus paper provides a general outline of the principles of iSTART and the scientific evidence behind them from the physicians' perspective. For future implementation, consideration of local factors in areas where iSTART is to be implemented will be necessary. In addition, patient involvement to guide the implementation of iSTART to match patients' requirements and treatment goals is necessary; but these considerations are better addressed at a local level to match the cultural situation and healthcare systems in a particular area.
CONSENSUS METHODS
An expert panel of gastroenterologists, including clinicians from Europe, Asia, Australia, and Latin America were assembled in Amsterdam to generate consensus on patient-centered second-line therapy in the form of the iSTART initiative. Supporting evidence was brought together from 3 literature reviews reflecting the global epidemiology of UC; mesalazine (5-ASA) treatment and its failure; second-line therapy and validated tools suitable for self-led patient assessment. Searches were performed using the PubMed, Embase, Cochrane Library and clinicaltrials.gov platforms. Advisors voted on draft consensus statements based on the evidence-based reviews and in line with current guidelines for mild-to-moderate UC. Advisors voted whether they "strongly agree, " "agree" or "disagree/uncertain" for each statement. A statement was passed if ≥ 75% of the panel agreed/strongly agreed with a statement; if consensus was not reached, statements were revised via group discussion. The agreed consensus was then used as the basis to produce a series of recommendations, which were voted on using the same methodology. A full list of consensus statements and the literature supporting them was compiled (Supplementary Material 1).
CURRENT TREATMENT REGIMEN
The current treatment protocol for mild-to-moderate UC is well established and is outlined in all major guidelines on UC.
10-12 5-ASA is the recommended first-line therapy for the induction and maintenance of remission in mild-to-moderate UC. [10] [11] [12] Although exact regimens vary depending on disease extent, the recommendations for the induction of remission are combination therapy consisting of rectal (1 g/day) and high dose oral 5-ASA (2-4 g/day). [10] [11] [12] This optimized 5-ASA therapy is designed to induce remission quickly and effectively; such regimens are able to induce remission in 50% to 70% of patients. 25 For patients that do not respond sufficiently to optimized 5-ASA, oral or rectal corticosteroids are the recommended second-line treatment in all major guidelines. [10] [11] [12] A key consideration in corticosteroid treatment is the adverse event profile often associated with these treatments, especially when a systemic mode of delivery is used, as corticosteroids are associated with a number of well-known side effects, such as adrenal suppression. 26, 27 To overcome the drawbacks of corticosteroid therapy, "second-generation" steroids have been developed, such as budesonide and more advanced formulations. 26, 27 Oral budesonide has a high first-pass metabolism which significantly reduces systemic exposure and it has been formulated for UC using MMX ® Multimatrix technology to provide a targeted colonic delivery. 26, 27 Budesonide MMX ® has shown high levels of efficacy in clinical trials, 28, 29 and equally as importantly no difference in adverse events to placebo (RR, 0.85; 95% CI, 0.53-1.38). 28 These characteristics make budesonide MMX ® a corticosteroid that has a profile suited to an initiative such as iSTART.
PATIENT-CENTERED TREATMENT IN UC
For an initiative such as iSTART to be successful requires reliable methods for patients to self-assess their condition. A number of simple indices for disease evaluation in UC have been developed that could be used by patients to monitor their disease. However, to have confidence in the use of such an index in clinical practice requires its validation. Three such validated indices that have been identified: the PRO2, the patient-reported UC activity index (PRUCSI) and the mobile health index for UC (mHI-UC). [30] [31] [32] The PRO2 uses 2 indicators, stool frequency and rectal bleeding, and has an area under the receiver operating characteristic curve (AUC) of 0.90 in a validation cohort using an endoscopy score of ≤ 1 to define remission (AUC was 0.80 when using a score of 0 to define remission). 30 The PRUCSI uses the 6-point Mayo score
with the addition of patient-defined "general well-being. " 31 The PRUCSI has a validated AUC of 0.91, with a sensitivity of 78% and specificity of 84%. 31 The mHI-UC incorporates patient-reported measurements derived from UC disease activity indices. 32 The mHI-UC uses 4 questions covering stool frequency, rectal bleeding, abdominal pain and overall well-being within a complex scoring system to define flares. 32 The mHI-UC has reported an AUC of over 0.91, with a sensitivity of 72% and a specificity of 90%. 32 AUC values of 0.8 or higher are accepted to show a good predictive value, and values of 0.9 or greater show an excellent predictive value. These results show that these 3 indices all have a strong power for identifying flares and the potential to be used within iSTART. Evidence of the benefits of patient-centered care in UC comes from a number of studies. In Denmark, a self-care web portal increased adherence in a validation group of 333 UC patients, and reduced the duration of relapses (18 days vs. 77 days for control cohort). [33] [34] [35] The UC home telemanagement system (UC HAT), from the United States, used self-reporting of symptoms through 14 computerized questions to produce treatment recommendations. 36, 37 A clinical trial of UC HAT found that it improved patient QoL compared to standard care. 37 A UK study used individualized patient-directed management plans to trigger additional treatment when a relapse occurred. 38 Compared to controls, this intervention caused a non-significant reduction in the average number of relapses (1.53 vs. 1.93), a significant reduction in time to treatment of a relapse (14.8 hours vs. 49.6 hours, P < 0.0001), a non-significant decrease in the length of flares and a significant decrease in average number of general practitioner and hospital visits (P < 0.0001).
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These studies show the potential of patient-centered management within UC, and the advantages for rapid treatment of flares for patients, clinicians and health systems.
CONCLUSIONS
Active disease in mild-to-moderate UC causes a significant health burden that can have a great impact on the daily life and QoL of those affected. The burden of disease in this group is particularly important with the increasing global incidence of UC and mild-to-moderate disease being the most common at diagnosis. There is therefore the potential for iSTART to have an impact on improving treatment in this large and important group of patients. Although optimized 5-ASA treatment is an effective firstline treatment, it is not sufficient to control active UC in all patients. Steroids are the accepted second-line treatment and oral bude sonide MMX ® should be considered as a preferred corticosteroid option for mild-to-moderate disease, due to its high efficacy and low incidence of steroid-related adverse events. Timely and appropriate access to second-line therapy is necessary to minimize the impact of active UC on both healthcare systems and patients.
The potential for patient-centered care in UC has been demonstrated in a number of studies. However, these have also shown that clear guidance and definitions are required for accurate self-reporting. A small number of validated patient-reported outcome measures for disease activity in UC have been developed. The use of these indices within iSTART should allow an accurate and rapid initiation of treatment for a flare. Whilst there are potential benefits to all patients from iSTART, clinicians should select only the most appropriate patients. iS-TART also makes clear to patients that upon experiencing a flare, they must contact their clinicians to allow their ongoing disease management to be reassessed. The recommendations of the expert panel are shown below, and these outline the basic principles of iSTART as have been summarized above.
RECOMMENDATIONS Recommendation 1:
In line with current treatment guidelines, it is recommended that the primary focus of treatment in UC is the rapid induction of remission followed by maintenance of this remission in the long-term.
(strongly agreed 90.0%; agreed 10.0%; disagreed 0.0%: CONS-ENSUS REACHED)
Recommendation 2: It is recommended that in the event of a flare, patients with mild-to-moderate UC should be treated as soon as possible to get them back into remission:
• Optimization of 5-ASA therapy to a high dose oral and/or rectal therapy should occur before any other therapy is considered • Rapid access to second-line therapies is important due to flares causing a clinical and economic impact that can be reduced by fast treatment (strongly agreed 50.0%; agreed 40.0%; disagreed 10.0%: CON-SENSUS REACHED) Recommendation 7: It is recommended that PRO2 and PRUCSI are appropriate patient-reported indices for self-assessment, as they are simple, validated and have a strong discriminatory power for flares:
• The PRO2 or PRUCSI can be used by patients to assess disease by monitoring changes in stool frequency and rectal bleeding • An increase in PRUCSI or PRO2 score of >1 over a 3-5 days could be used to identify a flare (strongly agreed 63.6%; agreed 27.4%; disagreed 9.0%: CON-SENSUS REACHED)
Recommendation 8:
The group recommends that a program such as iSTART could provide improved treatment of flares in UC patients.
(strongly agreed 72.7%; agreed 27.3%; disagreed 0.0%: CON-SENSUS REACHED)
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Epidemiology
The incidence and prevalence of UC has been documented in a number of systematic reviews, 1-3 with numerous primary epidemiological studies providing supporting evidence. There has been a rapid increase in the incidence and prevalence of UC since the mid-20th century across many countries. 1,2 The EpiCom study reported incidence rates in Europe of 4 to 19 per 100,000 in 2010, 4 with similar rates found in Canada, 1, 5, 6 and Australia; 1,7 whereas Asia and Latin America have lower rates of around 1 to 5 per 100,000. 1, 7, 8 The prevalence of UC in Europe, Canada and Australia has been estimated at 100 to 290 per 100,000. 1, 5, 6, 9, 10 Prevalence is lower across Asia and Latin America at 10 to 60 per 100,000. 1, 11, 12 Despite differences classification scales, the proportion classified with mild-to-moderate UC was 70% to 95% at diagnosis and therefore is the predominant form of the disease. [13] [14] [15] [16] [17] [18] Four disease courses have been described in UC: single relapse followed by sustained remission; intermittent relapses separated by remission periods; chronic active; and fulminant. The most common form of UC is an intermittent-relapsing course, affecting 40% to 60% of patients. [19] [20] [21] [22] A key consequence of active disease is an increased number and frequency of symptoms. 23 Symptoms that are more common in active UC compared to remission include fatigue, 24, 25 pain, 26 extraintestinal manifestations (EIMs), 27 and fecal incontinence. 28 Active disease has also been associated with depression, [29] [30] [31] anxiety, 30, 31 and sleep disruption. 32, 33 Symptoms disrupt daily life for 94% of patients during a flare, 34 leading to a reduced quality of life during active disease. [35] [36] [37] [38] Quality of life has been found to correlate the frequency of symptoms, 39 and the number of relapses experienced. 40, 41 Studies from many countries have shown that EQ-5D is significantly reduced during active compared to inactive disease. [42] [43] [44] Relapses in UC are associated with higher rates of physician, emergency and outpatient visits, [45] [46] [47] which leads to increased healthcare costs. 43, 45, 48 Furthermore, active UC also leads to increased absences from work, 49 and a higher likelihood of claiming a disability pension.
49,50
See "Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach" on page 522-528.
Statement 1:
The global incidence and prevalence of UC is rising (grade B) (strongly agreed 90.0%; agreed 10.0%; disagreed 0.0%: CONSENSUS REACHED) Statement 2: Mild-to-moderate disease is most prevalent at diagnosis (grade B) (strongly agreed 100%; statement revised and CONSENSUS REACHED via discussion) Statement 3: An intermittent-relapsing course is most common (grade B) (strongly agreed 60.0%; agreed 40.0%; disagreed 0.0%: CONSENSUS REACHED)
Statement 4:
Episodes of disease activity (in contrast to remission periods) are associated with a significantly decreased patient quality of life, a significant impact on daily life, and increased healthcare costs and burden (grade C) (strongly agreed 100%; statement revised and CONSENSUS REACHED via discussion)
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The largest available, recent dataset (EpiCom study) shows that 70% to 74% of patient were in remission at any time, with the remainder showing symptomatic disease. 51 These figures are supported by a Canadian systematic review that found 75% to 90% of patients were in remission at any time. 52 Longitudinal epidemiological studies have shown a gradual decrease in the rate of relapse over time after diagnosis. 53, 54 Similar data are seen for 5-ASA treated patients, [55] [56] [57] [58] and a longitudinal investigation of 5-ASA treatment clearly demonstrated the highest risk of relapse during the first 2 to 3 years after diagnosis. 56, 57 Around 50% of newly diagnosed patients have active disease at any time. 51, [59] [60] [61] The EpiCom study found that 89% of patients had active disease at diagnosis, which dropped to 59% after 3 months and 28% after 1 year. 51 The placebo arms in clinical trials give the best available estimate as to the effects of delayed treatment on disease activity. The rate of remission varies depending on the definition used, but overall these trials have shown a low rate of spontaneous remission in UC of around 17%. 62 However, the rate of remission in placebo-treated patients is lower (<10%) when a stricter definition of remission is used that incorporates clinical and endoscopic definitions. 63, 64 Around 30% of patients experience no relapses in a year and therefore around 70% experience at least 1 relapse. 43, 45, 65, 66 Only a small number of studies have attempted to quantify the difference in risk between patients who have had a flare and those who have not in the previous year. In a study from Norway, 30% of patients relapsed after a period of remission compared to 63% after a period of active disease, a 52% reduction (P < 0.001). 60 An Iranian study reported a 20% reduction in relapse rate for all patients compared to those with a previous relapse. 65 A Korean cohort study showed a 46.3% reduction in the relapse rate for patients who showed mucosal healing compared to those who did not (36.3% vs. 19.5%, P = 0.006). 67 These limited data were combined with the panel' s expert opinion to estimate risk reduction at 25%.
A survey of patients and clinicians found that physicians and nurses had a lower estimate of the number of relapses for each patient compared to the numbers self-reported; patients reported a mean of 5.5 flares over a year, versus estimates of 3.4 by doctors which implies the majority of this perception gap occurs due to non-disclosure of flares by patients to HCPs. 68 
First-Line Treatment and Treatment Failure
The treatment guidelines reviewed were those of the European Crohn' s and Colitis Organisation (ECCO), 69, 70 the Canadian Association of Gastroenterology (CAG), 71 the World Gastroenterology Organisation, 72 the American Gastroenterology Association, 73 the American College of Gastroenterology, 74 and the Pan American Crohn' s and Colitis Organization.
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Optimized 5-ASA therapy is a high dose oral regimen combined with a topical 5-ASA regimen designed to induce remission quickly and effectively. A recent Cochrane Review reported that high dose regimens of 5-ASA are able to induce remission in between 50% and 70% of UC patients. 62 Treatment failure is often not explicitly defined. Guidelines define UC treatment goals to be the induction and maintenance of remission; 70, 72, 74 this infers that treatment failure is an inability to meet these goals. The CAG guidelines define 5-ASA treatment failure to be the "inability of the patient to achieve and maintain complete corticosteroid-free remission despite optimal treatment with oral, rectal, or combination 5-ASA therapy. " 71 The opinion of the panel was that the ability to achieve and maintain remission are distinct occurrences and so they are presented as separate statements.
Where defined, guidelines define remission as a normal stool frequency (≤ 3/day) with no blood in stool and potential confirmation of mucosal healing. 69, 71 The guidelines define relapse/flare as the opposite of being in remission. 69, 71 The consensus was that remission is defined as a normal bowel frequency (≤ 3/day), absence of rectal bleeding and normal mucosal appearance on endoscopy, with relapse/flare defined as the opposite. There is little guidance available on the timescale over which symptoms need to be present for a flare to be determined. It was the opinion of the expert panel that these changes need to be present on consecutive days in order for a UC flare to be the most likely cause. The differentiation between a UC flare and Clostridium difficile infection can be challenging as symptoms can be identical. 76, 77 UC patients are at an increased risk for C. difficile infection, [76] [77] [78] both inside and outside the hospital setting. 78 However, the rate of The evidence regarding disease extent as a risk factor for treatment failure is mixed. However, a majority of studies showed a higher risk of relapse with a greater disease extent; particularly when considering proctitis versus a greater extent. 55, 58, 81 Fecal calprotectin (FC) levels have been identified as a potential predictor of relapse, and a meta-analysis found that FC had an overall sensitivity of 77% and a specificity of 71% as a predictive factor for relapse. 82 A variety of cutoff values have been used to define increased risk, varying from 50 mg/L to 200 μg/g. 83, 84 The expert panel was of the opinion that a lack of normalization of FC levels is the best measure to use as a risk factor for 5-ASA treatment failure. There is strong evidence that absence of mucosal healing is linked to 5-ASA treatment failure and an increased risk/rate of relapse. 17, [85] [86] [87] The presence of EIMs has been found to be associated with a higher rate of 5-ASA failure. 55, 81, 88 The ECCO guidelines describe the presence of EIMs as a possible risk factor for relapse in patients with quiescent disease. 70 A range of other potential risk factors for 5-ASA treatment failure have been identified, but all have a lack of supporting evidence. Possible risk factors include a lack education above high school level, 89 former smokers, 90 and being unmarried. 91, 92 ECCO guidelines describe multiple possible risk factors for relapse in patients with quiescent disease including stress and low-fiber diet. 70 Nonadherence is a well-established risk factor for 5-ASA failure, 70 but is hard to predict and has links to many of the other risk factors described here.
Second-Line Treatment and Self-Led Patient Assessment
Guidelines for patients with mild-to-moderate UC that do not respond sufficiently to optimized 5-ASA therapy are generally consistent, recommending corticosteroids as oral or rectal therapies (dependent on disease extent). 70, 71, 74, 75 A Cochrane analysis of budesonide MMX ® has shown that it can induce remission in 15% of patients versus 9% for placebo (RR, 2.25; 95% CI, 1.50-3.39), 93 with no difference in adverse events (RR, 0.85; 95% CI, 0.53-1.38). 93 Remission rates were low compared to other UC therapies due to the CORE I and CORE II studies using a strict definition of "combined clinical and endoscopic remission, " defined as a normal bowel frequency with no rectal bleeding and endoscopic remission based on a full colonoscopy.
